

## Literatura ACTA MEDICINAE 10/2020 Revmatologie

- 2 **Doporučení Evropské ligy proti revmatismu (EULAR) pro léčbu revmatoidní artritidy 2019**  
prof. MUDr. Karel Pavelka, DrSc. Revmatologický ústav, Praha
- 2 **Výběr pacienta vhodného pro léčbu sarilumabem na podkladě výstupů z lékových hodnocení**  
prof. MUDr. Ladislav Šenolt, Ph.D. Revmatologický ústav, Praha
- 2 **Upadacitinib v léčbě revmatoidní artritidy**  
prof. MUDr. Karel Pavelka, DrSc. Revmatologický ústav, Praha
- 3 **Benefity ibuprofenu z pohledu reumatologa**  
prof. MUDr. Ivan Rybár, Ph.D. Katedra reumatologie Lékařské fakulty Slovenskej zdravotníckej univerzity, Bratislava, Národný ústav reumatických chorôb, Piešťany, SR
- 3 **Antirevmatické léky asociované s rizikem fraktur u pacientů s revmatoidní artritidou**  
MUDr. Kristýna Brábníková Marešová, Ph.D. Revmatologický ústav, Revmatologická klinika 1. LF UK, Praha
- 3 **Tofacitinib a reálná klinická praxe při léčbě revmatoidní artritidy**  
MUDr. Šárka Forejtová Revmatologický ústav, Praha
- 4 **Metotrexát v léčbě revmatoidní artritidy a jak optimálně využít jeho potenciál**  
MUDr. Mária Filková, Ph.D. Revmatologický ústav, Praha
- 4 **Biosimilární etanercept: GP2015 (Erelzi)**  
MUDr. David Suchý, Ph.D. Oddělení klinické farmakologie FN Plzeň
- 5 **Léčba bolesti u revmatických onemocnění**  
MUDr. Marta Olejárová, CSc. Revmatologický ústav a Revmatologická klinika 1. LF UK, Praha
- 5 **Lokální nesteroidní antirevmatika v léčbě bolesti u osteoartrózy**  
MUDr. Olga Šléglová Revmatologický ústav a Klinika revmatologie 1. LF UK, Praha
- 5 **Dexketoprofen v léčbě bolesti**  
MUDr. Marek Hák, Ph.D. Centrum léčby bolesti, Medicinicare, s. r. o., Chirurgická klinika FN a LF MU, Brno
- 5 **Secukinumab v léčbě non-radiografické axiální spondyloartritidy**  
prof. MUDr. Karel Pavelka, DrSc. Revmatologický ústav, Praha
- 6 **Cesta k nové léčebné možnosti v terapii autoimunit: anti-IL-17A ixekizumab**  
MUDr. Markéta Hušáková, Ph.D. Revmatologický ústav, Praha
- 6 **Febuxostat 80 mg – lékový profil**  
doc. MUDr. Petr Němec, Ph.D. Revmatologická ambulance II. interní kliniky, FN u sv. Anny v Brně a LF MU, Brno
- 6 **Mukopolysacharidóza I**  
doc. RNDr. MUDr. Pavel Ješina, Ph.D. Metabolické centrum, Klinika pediatrie a dědičných poruch metabolismu 1. LF UK a VFN, Praha
- 7 **Kardiovaskulární riziko při léčbě inhibitory Janus kináz v revmatologii**  
MUDr. Sabína Oreská Revmatologický ústav a Revmatologická klinika, 1. LF UK, Praha
- 8 **Plicní arteriální hypertenze u systémových onemocnění pojiva**  
doc. MUDr. Radim Bečvář, CSc. Revmatologický ústav a Revmatologická klinika 1. LF UK, Praha
- 8 **Pleiotropní efekt vitamínu D**  
doc. MUDr. Václav Vyskočil, Ph.D. II. interní klinika – klinika ortopedie a traumatologie pohybového ústrojí LF UK a FN Plzeň

# Doporučení Evropské ligy proti revmatismu (EULAR) pro léčbu revmatoidní artritidy 2019

prof. MUDr. Karel Pavelka, DrSc. Revmatologický ústav, Praha

- 1 Smolen, J. S. – Landewé, R. B. – Bijlsma, W. J. J., et al.: EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. *Ann Rheum Dis*, 2020, 79, s. 685–699.
- 2 Aletaha, D. – Neogi, T. – Silman, A. J., et al.: 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League against rheumatism collaborative initiative. *Arthritis Rheum*, 2010, 62, s. 2569–2581.
- 3 Felson, D. T. – Smolen, J. S. – Wells, G., et al.: American College of Rheumatology/European League against rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. *Ann Rheum Dis*, 2011, 70, s. 404–413.
- 4 Smolen, J. S. – Breedveld, F. C. – Burmester, G. R., et al.: Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international Task force. *Ann Rheum Dis*, 2016, 75, s. 3–15.
- 5 Aletaha, D. – Smolen, J. S.: Diagnosis and management of rheumatoid arthritis. *JAMA*, 2018, 320, s. 1360–1372.
- 6 Smolen, J. S. – Aletaha, D. – Gruben, D., et al.: Brief report: remission rates with tofacitinib treatment in rheumatoid arthritis: a comparison of various remission criteria. *Arthritis Rheumatol*, 2017, 69, s. 728–734.
- 7 Visser, K. – van der Heijde, D.: Optimal dosage and route of administration of methotrexate in rheumatoid arthritis: a systematic review of the literature. *Ann Rheum Dis*, 2009, 68, s. 1094–1099.
- 8 Goekoop-Ruiterman, Y. P. M., et al.: Comparison of treatment strategies in early rheumatoid arthritis. *Ann Intern Med*, 2007, 146, s. 406–415.
- 9 Taylor, P. C. – Keystone, E. C. – van der Heijde, D., et al.: Baricitinib versus placebo or adalimumab in rheumatoid arthritis. *N Engl J Med*, 2017, 376, s. 652–662.
- 10 Fleischmann, R. – Pangan, A. L. – Song, I.-H., et al.: Upadacitinib versus placebo or adalimumab in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase III, double-blind, randomized controlled trial. *Arthritis Rheumatol*, 2019, 71, s. 1788–1800.
- 11 Fleischmann, R. – Mysler, E. – Hall, S., et al.: Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (oral strategy): a phase 3b/4, double-blind, head-to-head, randomised controlled trial. *Lancet*, 2017, 390, s. 4457–4468.
- 12 Combe, B. – Kivitz, A. – Tanaka, Y., et al.: Efficacy and safety of filgotinib for patients with rheumatoid arthritis with inadequate response to methotrexate: finch 1 primary outcome results. *Ann Rheum Dis*, 2019, 78, s. 77–78.
- 13 Burmester, G. R. – Kivitz, A. J. – Kupper, H., et al.: Efficacy and safety of ascending methotrexate dose in combination with adalimumab: the randomised CONCERTO trial. *Ann Rheum Dis*, 2015, 47, s. 1037–1044.

## Výběr pacienta vhodného pro léčbu sarilumabem na podkladě výstupů z lékových hodnocení

prof. MUDr. Ladislav Šenolt, Ph.D. Revmatologický ústav, Praha

- 1 Šenolt, L.: Revmatoidní artritida. *Vnitřní lékařství*, 2018, 64, s. 98–106.
- 2 Romano, S. – Salustri, E. – Ruscitti, P., et al.: Cardiovascular and metabolic comorbidities in rheumatoid arthritis. *Curr Rheumatol Rep*, 2018, 20, s. 81.
- 3 Hanova, P. – Pavelka, K. – Dostal, C., et al.: Epidemiology of rheumatoid arthritis, juvenile idiopathic arthritis and gout in two regions of the Czech Republic in a descriptive population-based survey in 2002–2003. *Clin Exp Rheumatol*, 2006, 24, s. 499–507.
- 4 Romão, V. C. – Vital, E. M. – Fonseca, J. E., et al.: Right drug, right patient, right time: aspiration or future promise for biologics in rheumatoid arthritis? *Arthritis Res Ther*, 2017, 19, s. 239.
- 5 Aletaha, D. – Smolen, J. S.: Diagnosis and management of rheumatoid arthritis: a review. *JAMA*, 2018, 320, s. 1360–1372.
- 6 Favalli, E. G. – Matucci-Cerinic, M. – Szekanez, Z.: The Giants (biologics) against the Pigmyes (small molecules), pros and cons of two different approaches to the disease modifying treatment in rheumatoid arthritis. *Autoimmun Rev*, 2020, 19, s. 102421.
- 7 Lamb, Y. N. – Deeks, E. D.: Sarilumab: a review in moderate to severe rheumatoid arthritis. *Drugs*, 2018, 78, s. 929–940.
- 8 Madhok, R. – Crilly, A. – Watson, J., et al.: Serum interleukin 6 levels in rheumatoid arthritis: correlations with clinical and laboratory indices of disease activity. *Ann Rheum Dis*, 1993, 52, s. 232–234.
- 9 Ponzetti, M. – Rucci, N.: Updates on osteoimmunology: What's new on the cross-talk between bone and immune system. *Front Endocrinol (Lausanne)*, 2019, 10, s. 236.
- 10 Huizinga, T. W. – Fleischmann, R. M. – Jasson, M., et al.: Sarilumab, a fully human monoclonal antibody against IL-6Ra in patients with rheumatoid arthritis and an inadequate response to methotrexate: efficacy and safety results from the randomised SARIL-RA-MOBILITY Part A trial. *Ann Rheum Dis*, 2014, 73, s. 1626–1634.
- 11 Genovese, M. C. – Fleischmann, R. – Kivitz, A. J., et al.: Sarilumab plus methotrexate in patients with active rheumatoid arthritis and inadequate response to methotrexate: results of a phase III study. *Arthritis Rheumatol*, 2015, 67, s. 1424–1437.
- 12 Fleischmann, R. – van Adelsberg, J. – Lin, Y., et al.: Sarilumab and nonbiologic disease-modifying antirheumatic drugs in patients with active rheumatoid arthritis and inadequate response or intolerance to tumor necrosis factor inhibitors. *Arthritis Rheumatol*, 2017, 69, s. 277–290.
- 13 Burmester, G. R. – Lin, Y. – Patel, R., et al.: Efficacy and safety of sarilumab monotherapy versus adalimumab monotherapy for the treatment of patients with active rheumatoid arthritis (MONARCH): a randomised, double-blind, parallel-group phase III trial. *Ann Rheum Dis*, 2017, 76, s. 840–847.
- 14 Strand, V. – Gossec, L. – Proudfoot, C. W. J., et al.: Patient-reported outcomes from a randomized phase III trial of sarilumab monotherapy versus adalimumab monotherapy in patients with rheumatoid arthritis. *Arthritis Res Ther*, 2018, 20, s. 129.
- 15 Genovese, M. C. – van Adelsberg, J. – Fan, C., et al.: Two years of sarilumab in patients with rheumatoid arthritis and inadequate response to MTX: safety, efficacy and radiographic outcomes. *Rheumatology (Oxford)*, 2018, 57, s. 1423–1431.
- 16 Genovese, M. C. – van der Heijde, D. – Lin, Y., et al.: Long-term safety and efficacy of sarilumab plus methotrexate on disease activity, physical function and radiographic progression: 5 years of sarilumab plus methotrexate treatment. *RMD Open*, 2019, 5, s. e000887.
- 17 Burmester, G. R. – Strand, V. – Rubbert-Roth, A., et al.: Safety and efficacy of switching from adalimumab to sarilumab in patients with rheumatoid arthritis in the on going MONARCH open-label extension. *RMD Open*, 2019, 5, s. e001017.
- 18 Fleischmann, R. – Genovese, M. C. – Lin, Y., et al.: Long-term safety of sarilumab in rheumatoid arthritis: an integrated analysis with up to 7 years' follow-up. *Rheumatology (Oxford)*, 2020, 59, s. 292–302.
- 19 Šenolt, L. – Mann, H. – Závada, J. – Pavelka, K. – Vencovský, J.: Doporučení České revmatologické společnosti pro farmakoterapii revmatoidní artritidy 2017. *Česká revmatologie*, 2017, 25, s. 3–18.
- 20 Smolen, J. S. – Landewé, R. B. M. – Bijlsma, J. W. J., et al.: EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. *Ann Rheum Dis*, 2020, 79, s. 685–699.
- 21 Boyapati, A. – Schwartzman, S. – Mshid, J., et al.: High serum interleukin-6 is associated with severe progression of rheumatoid arthritis and increased treatment response differentiating sarilumab from adalimumab or methotrexate in a post hoc analysis. *Arthritis Rheumatol*, 2020, 10.1002/art.41299, publikováno před tiskem 28. 4. 2020.
- 22 Gabay, C. – Burmester, G. R. – Strand, V., et al.: Sarilumab and adalimumab differential effects on bone remodelling and cardiovascular risk biomarkers, and predictions of treatment outcomes. *Arthritis Res Ther*, 2020, 22, s. 70.

## Upadacitinib v léčbě revmatoidní artritidy

prof. MUDr. Karel Pavelka, DrSc. Revmatologický ústav, Praha

- 1 Myasoedova, E. – Crowson, C. S. – Kremers, H. M., et al.: Is the incidence of rheumatoid arthritis rising: results from Olmsted County, Minnesota, 1955–2007. *Arthritis Rheum*, 2010, 62, s. 1576–1582.
- 2 Schindler, C. – Levy, D. E. – Dector, T.: JAK-STAT signalling from interferons to cytokines. *J Biol Chem*, 2007, 282, s. 20059–20063.
- 3 Schwartz, D. M. – Bonelli, M. – Gadina, M., et al.: Type I/II cytokines, JAKs, and new strategies for treating autoimmune diseases. *Nat Rev Rheumatol*, 2016, 12, s. 25–36.
- 4 Meyer, D. M. – Jessan, M. I. – Li, X., et al.: Anti-inflammatory activity and neutrophil reductions, mediated by the JAK-1/JAK-3 inhibitor CP-690, 550, in rat adjuvant-induced arthritis. *J Inflamm*, 2010, 7, s. 41.
- 5 Fridman, J. S. – Scherle, P. A. – Collins, R., et al.: Selective inhibition of JAK1 and JAK2 is efficacious in rodent models of arthritis: preclinical characterization of INCB028050. *J Immunol*, 2010, 184, s. 5298–5307.
- 6 Voss, J. – Graff, C. – Schwartz, A., et al.: Pharmacodynamics of novel JAK 1 selective inhibitor in rat arthritis and anemia models and in healthy human subjects. *Arthritis Rheum*, 2013, 65, suppl. 10.
- 7 Van Rompaey, L. – Galien, R. – van der Ar, E. M.: Preclinical characterization of GLPG0634, a selective inhibitor of JAK 1 for the treatment of inflammatory diseases. *J Immunol*, 2013, 191, s. 3568–3577.
- 8 Taylor, P.: Clinical efficacy of launched JAK inhibitors in rheumatoid arthritis. *Rheumatology*, 2019, 58, s. 17–26.
- 9 Fleischmann, R. – Mysler, E. – Hall, S., et al.: Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): a phase 3b/4, double-blind, head-to-head, randomised controlled trial. *Lancet*, 2017, 390, s. 457–468.
- 10 Kunwar, S. – Collins, C. H. – Constantinescu, F.: Baricitinib, a Janus kinase inhibitor in the treatment of rheumatoid arthritis: a systematic literature review and meta-analysis of randomized controlled trials. *Clinical Rheumatology*, 2018, 37, s. 2611–2620.
- 11 Mohamed, E. – Klünder, B. – Othman, A. A.: Clinical pharmacokinetics of upadacitinib: Review of data relevant to the rheumatoid arthritis indication. *Clin Pharmacokinet*, 2019, <https://doi.org/10.1007/s40262-019-00855-0>.
- 12 van Vollenhoven, R. – Takeuchi, T. – Pangan, A. L., et al.: A phase 3, randomized, controlled trial comparing upadacitinib monotherapy to MTX monotherapy in MTX-naïve patients with active rheumatoid arthritis. 2018 ACR/ARHP Annual Meeting. 21. 10. 2018, abstrakt 891.
- 13 Smolen, J. – Pangan, A. L. – Emery, P., et al.: Upadacitinib as monotherapy in patients with active rheumatoid arthritis and inadequate response to MTX (SELECT-MONOTHERAPY) a randomised, placebo-controlled, double blind phase 3 study. *Lancet*, 2019, 393, s. 2303–2311.
- 14 Fleischmann, R. – Pangan, A. L. – Song, I. H., et al.: Upadacitinib Versus placebo or adalimumab in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase III, double-blind, randomized controlled trial. *Arthritis Rheumatol*, 2019, 71, s. 1788–1800.
- 15 Fleischmann, R. – Genovese, M. C. – Enejosa, J. V., et al.: Safety effectiveness of upadacitinib or adalimumab plus MTX in patients with rheumatoid arthritis over 48 weeks with switch to alternate therapy in patients with insufficient response. *Ann Rheum Dis*, 2019, 78, s. 1454–1462.
- 16 Genovese, M. C. – Fleischmann, R. – Combe, B., et al.: Safety and efficacy of upadacitinib in patients with active rheumatoid arthritis refractory to biologic disease-modifying antirheumatic drugs: SELECT-Beyond: A double-blind, randomized controlled phase 3 trial. *Lancet*, 2018, 391, s. 2513–2524.
- 17 Strand, V. – Schiff, M. – Tundia, N., et al.: Effects of upadacitinib on patient – reported outcomes: results from SELECT-Beyond, a phase 3 randomized trial in patients with rheumatoid arthritis and inadequate responses to biologic disease-modifying antirheumatic drugs. *Arthritis Res Ther*, 2019, 21, s. 263.
- 18 Cohen, S. B. – van Vollenhoven, R. – Winthrop, K., et al.: Safety profile of upadacitinib in rheumatoid arthritis: Integrated analyses from the

SELECT phase 3 clinical program. European Congress of Rheumatology, Madrid, Španělsko, 2019, THU0167, abstrakt.

19 **Winthrop, K. L. – Yamanaka, H. – Valdez, H., et al.**: Herpes zoster and tofacitinib therapy in patients with rheumatoid arthritis. *Arthritis Rheumatol*, 2014, 66, s. 2675–2684.

20 **Solomon, D. H. – Karlson, E. W. – Rimm, E. B., et al.**: Cardiovascular morbidity and mortality in women diagnosed with rheumatoid arthritis. *Circulation*, 2003, 107, s. 1303–1307.

21 **Choy, E. – McInnes, I. – Cush, J., et al.**: MACC and VTE across multiple

upadacitinib studies in rheumatoid arthritis: integrated analysis from the SELECT phase 3 clinical program. *Arthritis & Rheumatology*, 2019, 71, Meeting Abstract: 0846.

22 **Wollenhaupt, J. – Lee, E. B. – Curtis, J. R., et al.**: Safety and efficacy of tofacitinib for up to 9.5 years in the treatment of rheumatoid arthritis: final results of a global, open-label, long-term extension study. *Arthritis Res Ther*, 2019, 21, s. 89.

23 Dostupné z: <https://www.eur.europa.eu/en/medicines/human/refserrals/xeljanz>, vyhledáno 19. 3. 2020.

24 **Parmentier, J. M., et al.**: In vitro and in vivo characterization of the JAK1 selectivity of upadacitinib (ABT-494). *BMC Rheumatol*, 2018, 28, s. 23.

25 **Smolen, J. S. – van der Heijde, D. – Machold, K. P., et al.**: Proposal for a new nomenclature of disease-modifying antirheumatic drugs. *Ann Rheum Dis*, 2014, 73, s. 3–5.

26 **Biggioggero, M., Becciolini, A. – Crotti, Ch., et al.**: Upadacitinib and filgotinib: the role of JAK1 selective inhibition in the treatment of rheumatoid arthritis. *Drugs in Context*, 2019, 8, 212595.

## Benefity ibuprofenu z pohľadu reumatológa

prof. MUDr. Ivan Rybár, Ph.D. Katedra reumatológie Lekárskej fakulty Slovenskej zdravotníckej univerzity, Bratislava, Národný ústav reumatických chorôb, Piešťany, SR

1 **Davies, N. M.**: Clinical pharmacokinetics of ibuprofen. The first 30 years. *Clin Pharmacokinet*, 1998, 34, s. 101–154.

2 **Rainsford, K. D.**: Ibuprofen: pharmacology, efficacy and safety. *Inflammopharmacology*, 2009, 17, s. 275–342.

3 **Dominkus, M. – Nicolakis, M. – Kotz, R., et al.**: Comparison of tissue and plasma levels of ibuprofen after oral and topical administration. *Arzneimittelforschung*, 1996, 46, s. 1138–1143.

4 **Day, R. O. – Williams, K. M. – Graham, G. G., et al.**: Stereoselective disposition of ibuprofen enantiomers in synovial fluid. *Clin Pharmacol Ther*, 1988, 43, s. 480–487.

5 **Mäkelä, A. L. – Lempiäinen, M. – Vlijoki, H.**: Ibuprofen levels in serum and synovial fluid. *Scand J Rheumatol Suppl*, 1981, 39, s. 15–17.

6 **McGettigan, P. – Henry, D.**: Cardiovascular risk and inhibition of cyclooxygenase: a systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase 2. *JAMA*, 2006, 296, s. 1633–1644.

7 **Kellstein, D. E. – Waksman, J. A. – Furey, S. A., et al.**: The safety profile of nonprescription ibuprofen in multiple-dose use: a meta-analysis. *J Clin Pharmacol*, 1999, 39, s. 520–532.

8 **Southey, E. R. – Soares-Weiser, K. – Kleijnen, J.**: Systematic review and meta-analysis of the clinical safety and tolerability of ibuprofen compared with paracetamol in paediatric pain and fever. *Curr Med Res Opin*, 2009, 25, s. 2207–2222.

9 **Bello, A. E. – Kent, J. D. – Grah, A. Y., et al.**: Risk of upper

gastrointestinal ulcers in patients with osteoarthritis receiving single-tablet ibuprofen/famotidine versus ibuprofen alone: pooled efficacy and safety analyses of two randomized, double-blind, comparison trials. *Postgrad Med*, 2014, 126, s. 82–91.

10 **Rinott, E. – Kozler, E. – Shapira, Y., et al.**: Ibuprofen use and clinical outcomes in COVID-19 patients. *Clin Microbiol Infect*, 2020, S1198-743X(20)30343–30348.

11 **Kutti Sridharan, G. – Kotagiri, R. – Chandiramani, V. H.**: COVID-19 and avoiding ibuprofen. How good is the evidence? *Am J Ther*, 2020, 27, s. e400–e402.

## Antirevmatické léky asociované s rizikom fraktur u pacientů s revmatoidní artritidou

MUDr. Kristýna Brábníková Marešová, Ph.D. Revmatologický ústav, Revmatologická klinika 1. LF UK, Praha

1 **Stemmler, F. – Simon, D. – Liphardt, A.-M., et al.**: Biomechanical properties of bone are impaired in patients with ACPA-positive rheumatoid arthritis and associated with the occurrence of fractures. *Ann Rheum Dis*, 2018, 77, s. 973–980.

2 **Guler-Yuksele, M. – Bijsterbosch, J. – Goekoop-Ruiterman, Y. P. M., et al.**: Changes in bone mineral density in patients with recent onset, active rheumatoid arthritis. *Ann Rheum Dis*, 2008, 67, s. 823–828.

3 **McInnes, I. B. – Schett, G.**: The pathogenesis of rheumatoid arthritis. *N Engl J Med*, 2011, 365, s. 2205–2219.

4 **Haugeberg, G. – Uhlig, T. – Falch, J. A., et al.**: Bone mineral density and frequency of osteoporosis in female patients with rheumatoid arthritis: Results from 394 patients in the Oslo County Rheumatoid Arthritis Register. *Arthritis Rheum*, 2000, 43, s. 522–530.

5 **van Staa, T. P. – Geusens, P. – Bijl, J. W. J., et al.**: Clinical assessment of the long-term risk of fracture in patients with rheumatoid arthritis. *Arthritis Rheum*, 2006, 54, s. 3104–3112.

6 **Sinagaglia, L. – Nervetti, A. – Mela, Q., et al.**: A multicenter cross-sectional study on bone mineral density in rheumatoid arthritis. Italian Study Group on Bone Mass in Rheumatoid Arthritis. *J Rheumatol*, 2000, 27, s. 2582–2589.

7 **Avina-Zubieta, J. A. – Thomas, J. – Sadatsafavi, M., et al.**: Risk of incident cardiovascular events in patients with rheumatoid arthritis: a meta-analysis of observational studies. *Ann Rheum Dis*, 2012, 71, s. 1524–1529.

8 **Matcham, F. – Rayner, L. – Steer, S., et al.**: The prevalence of depression in rheumatoid arthritis: a systematic review and meta-analysis. *Rheumatology (Oxford)*, 2013, 52, s. 2136–2148.

9 **Myasoedova, E. – Matteson, E. L. – Talley, N. J., et al.**: Increased incidence and impact of upper and lower gastrointestinal events in patients with rheumatoid arthritis in Olmsted County, Minnesota: a longitudinal population-based study. *J Rheumatol*, 2012, 39, s. 1355–1362.

10 **Lin, Y. C. – Li, Y. H. – Chang, C. H., et al.**: Rheumatoid arthritis patients with hip fracture: a nation wide study. *Osteoporos Int*, 2015, 26, s. 811–817.

11 **Šenolt, L. – Mann, H. – Závada, J., et al.**: *Doporučení České reumatologické společnosti pro farmakologickou léčbu revmatoidní artritidy 2017*. Revmatologický ústav, 2017, Klinika reumatologie 1. LF UK, Praha.

12 **Ozen, G. – Pedro, S. – Wolfe, F., et al.**: Medications associated with fracture risk in patients with rheumatoid arthritis. *Ann Rheum Dis*, 2019, 78, s. 1041–1047.

13 **Balasuubramanian, A. – Wade, S. W. – Adler, R. A., et al.**: Glucocorticoid exposure and fracture risk in patients with new-onset rheumatoid arthritis. *Osteoporos Int*, 2016, 27, s. 3239–3249.

14 **Coulson, K. A. – Reed, G. – Gilliam, B. E., et al.**: Factors influencing fracture risk, T score, and management of osteoporosis in patients with rheumatoid arthritis in the Consortium of Rheumatology Researchers of North America (CORRONA) registry. *J Clin Rheumatol*, 2009, 15, s. 155–160.

15 **Roussy, J. P. – Bessette, L. – Bernatsky, S., et al.**: Biologic disease-modifying anti-rheumatic drugs and the risk of non-vertebral osteoporotic fractures in patients with rheumatoid arthritis aged 50 years and over. *Osteoporos Int*, 2013, 24, s. 2483–2492.

16 **Kawai, V. K. – Grijalva, C. G. – Arbogast, P. G., et al.**: Initiation of tumor

necrosis factor a antagonists and risk of fractures in patients with selected rheumatic and autoimmune diseases. *Arthritis Care Res (Hoboken)*, 2013, 65, s. 1085–1094.

17 **Kim, S. Y. – Schneeweiss, S. – Liu, J., et al.**: Effects of disease-modifying antirheumatic drugs on nonvertebral fracture risk in rheumatoid arthritis: a population-based cohort study. *J Bone Miner Res*, 2012, 27, s. 789–796.

18 **Lange, U. – Teichmann, J. – Müller-Ladner, U., et al.**: Increase in bone mineral density of patients with rheumatoid arthritis treated with anti-TNF-alpha antibody: a prospective open-label pilot study. *Rheumatology (Oxford)*, 2005, 44, s. 1546–1548.

19 **Acurcio, F. A. – Moura, C. S. – Bernatsky, S., et al.**: Opioid use and risk of nonvertebral fractures in adults with rheumatoid arthritis: a nested case-control study using administrative databases. *Arthritis Rheumatol*, 2016, 68, s. 83–91.

20 **Zamora-Legoff, J. A. – Myasoedova, E. – Matteson, E. L., et al.**: Drug prescribing trends in adults with rheumatoid arthritis: a population-based comparative study from 2005 to 2014. *Clin Rheumatol*, 2016, 35, s. 2427–2436.

21 **An, T. – Hao, J. – Sun, S., et al.**: Efficacy of statins for osteoporosis: a systematic review and meta-analysis. *Osteoporos Int*, 2017, 28, s. 47–57.

22 **Oryan, A. – Kamali, A. – Moshiri, A.**: Potential mechanisms and applications of statins on osteogenesis: Current modalities, conflicts and future directions. *J Control Release*, 2015, 215, s. 12–24.

## Tofacitinib a reálná klinická praxe při léčbě revmatoidní artritidy

MUDr. Šárka Forejtová Revmatologický ústav, Praha

1 **Lee, E. B. – Fleischmann, R. – Hall, S.**: ORAL Start Investigators: Tofacitinib versus methotrexate in rheumatoid arthritis. *N Engl J Med*, 2014, 370, s. 2377–2386.

2 **Fleischmann, R. – Kremer, J. – Cush, J., et al.**: Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis. *N Engl J Med*, 2012, 367, s. 495–507.

3 **van Vollenhoven, R. F. – Fleischmann, R. – Cohen, S.**: ORAL Standard Investigators: Tofacitinib or adalimumab versus placebo in rheumatoid arthritis. *N Engl J Med*, 2012, 367, s. 508519.

4 **Kremer, J. – Li, G. – Hall, S., et al.**: Tofacitinib in combination with nonbiologic disease-modifying anti-rheumatic drugs in patients with active rheumatoid arthritis: a randomized trial. *Ann Intern Med*, 2013, 159, s. 253–261.

5 **van der Heijde, D. – Tanaka, Y. – Fleischmann, R.**: ORAL Scan Investigators: Tofacitinib (CP-690,550) in patients with rheumatoid arthritis receiving methotrexate: twelve-month data from a twenty-four-month phase III randomized radiographic study. *Arthritis Rheum*, 2013, 65, s. 559–570.

6 **Burmester, G. – Blanco, R. – Charles-Schoeman, C., et al.**: Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial. *Lancet*, 2013, 381, s. 415–460.

7 **Fleischmann, R. – Mysler, E. – Hall, S.**: ORAL Strategy investigators: Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): a phase 3b/4, double-blind, head-to-head, randomised controlled trial. *Lancet*, 2017, 390, s. 457–468.

8 **Wollenhaupt, J. – Lee, E. B. – Curtis, J. R., et al.**: Safety and efficacy of tofacitinib for up to 9.5 years in the treatment of rheumatoid arthritis: final results of a global, open-label, long-term extension study.

*Arthritis Res Ther*, 2019, 21, s. 89.

9 **Reed, G. W. – Gerber, R. A. – Shan, Y., et al.**: Real-world comparative effectiveness of tofacitinib and tumor necrosis factor inhibitors as monotherapy and combination therapy for treatment of rheumatoid arthritis. *Rheumatol Ther*, 2019, 6, s. 573–586.

10 **Harnett, J. – Gerber, R. – Gruben, D., et al.**: Evaluation of real-world experience with tofacitinib compared with adalimumab, etanercept, and abatacept in RA patients with 1 previous biologic DMARD: Data from a U. S. Administrative Claims Database. *J Manag Care Spec Pharm*, 2016, 22, s. 1457–1471.

11 **Finckh, A. – Tellenbach, C. – Herzog, L., et al.**: Comparative effectiveness of antitumor necrosis factor agents, biologics with an alternative mode of action and tofacitinib in an observational cohort of patients with rheumatoid arthritis in Switzerland. *RMD Open*, 2020, 6, s. e001174.

12 **Mueller, R. B. – Hasler, C. – Popp, F., et al.**: Effectiveness, tolerability,

- and safety of tofacitinib in rheumatoid arthritis: a retrospective analysis of real-world data from the St. Gallen and Aarau Cohorts. *J Clin Med*, 2019, 8, s. 1548.
- 13 **Poppe, J.** – Bessette, L. – Jones, N., et al.: Experience with tofacitinib in Canada: patient characteristics and treatment patterns in rheumatoid arthritis over 3 years. *Rheumatology* (Oxford), 2020, 59, s. 568–574.
- 14 **Iwamoto, N.** – Tsuji, S. – Takatani, A., et al.: Efficacy and safety at 24 weeks of daily clinical use of tofacitinib in patients with rheumatoid arthritis. *PLoS One*, 2017, 12, s. e0177057.
- 15 **Mori, S.** – Yoshitama, T. – Ueki, Y.: Tofacitinib therapy for rheumatoid arthritis: a direct comparison study between biologic-naïve and experienced patients. *Intern Med*, 2018, 57, s. 663–670.
- 16 **Cohen, S.** – Curtis, J. R. – DeMasi, R., et al.: World wide, 3-year, post-marketing surveillance experience with tofacitinib in rheumatoid arthritis. *Rheumatol Ther*, 2018, 5, s. 283–291.
- 17 **Kremer, J.** – Cappelli, L. C. – Etzel, C. J., et al.: Real-world data from a post-approval safety surveillance study of tofacitinib vs biologic DMARDs and conventional synthetic DMARDs: five-year results from a US-based rheumatoid arthritis registry. American College of Rheumatology, ACR Pediatric Rheumatology Symposium, 29. 4. 2018, Hyatt Regency New Orleans; 2018 ACR/ARHP Annual Meeting. Abstrakt 1542.
- 18 **Curtis, J. R.** – Xie, F. – Yun, H., et al.: Real-world comparative risks of herpes virus infections in tofacitinib and biologic-treated patients with rheumatoid arthritis. *Ann Rheum Dis*, 2016, 75, s. 1843–1847.
- 19 **Curtis, J. R.** – Xie, F. – Yang, S., et al.: Risk for herpes zoster in tofacitinib-treated rheumatoid arthritis patients with and without concomitant methotrexate and glucocorticoids. *Arthritis Care Res* (Hoboken), 2019, 71, s. 1249–1254.
- 20 **Desai, D.** – Mehta, D. – Mathias, P., et al.: Health care utilization and burden of diabetic ketoacidosis in the U.S. over the past decade: a nationwide analysis. *Diabetes Care*, 2018, 41, s. 1631–1638.
- 21 **Bird, P.** – Littlejohn, G. – Butcher, B., et al.: Evaluation of effectiveness and usage patterns of tofacitinib in treatment of rheumatoid arthritis in Australia: an analysis from the OPAL-QUMI real world dataset. *Arthritis Rheumatol*, 2019, 71, suppl. 10.

## Metotrexát v léčbě revmatoidní artritidy a jak optimálně využít jeho potenciál

MUDr. Mária Filková, Ph.D. Revmatologický ústav, Praha

- 1 **Smolen, J. S.** – Landewe, R. B. M. – Bijlsma, J. W. J., et al.: EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. *Ann Rheum Dis*, 22. 1. 2020, doi.org/10.1136/annrheumdis-2019-216655.
- 2 **Smolen, J. S.** – van der Heijde, D. – Machold, K. P., et al.: Proposal for a new nomenclature of disease-modifying antirheumatic drugs. *Ann Rheum Dis*, 2014, 73, s. 3–5.
- 3 **Taylor, P. C.** – Balsa Criado, A. – Mongey, A. B., et al.: How to get the most from methotrexate (MTX) treatment for your rheumatoid arthritis patient? MTX in the treat-to-target strategy. *J Clin Med*, 2019, 8, s. 515.
- 4 **Dalrymple, J. M.** – Stamp, L. K. – O'Donnell, J. L., et al.: Pharmacokinetics of oral methotrexate in patients with rheumatoid arthritis. *Arthritis Rheum*, 2008, 58, s. 3299–3308.
- 5 **Brown, P. M.** – Pratt, A. G. – Isaacs, J. D.: Mechanism of action of methotrexate in rheumatoid arthritis, and the search for biomarkers. *Nat Rev Rheumatol*, 2016, 12, s. 731–742.
- 6 **Hamilton, R. A.** – Kremer, J. M.: Why intramuscular methotrexate may be more efficacious than oral dosing in patients with rheumatoid arthritis. *Br J Rheumatol*, 1997, 36, s. 86–90.
- 7 **Schiff, M. H.** – Jaffe, J. S. – Freundlich, B.: Head-to-head, randomised, crossover study of oral versus subcutaneous methotrexate in patients with rheumatoid arthritis: drug-exposure limitations of oral methotrexate at doses  $\geq 15$  mg may be overcome with subcutaneous administration. *Ann Rheum Dis*, 2014, 73, s. 1549–1551.
- 8 **Hughes, C. D.** – Scott, D. L. – Ibrahim, F.; Investigators TP: Intensive therapy and remissions in rheumatoid arthritis: a systematic review. *BMC musculoskeletal disorders*, 2018, 19, s. 389.
- 9 **Gaujoux-Viala, C.** – Rincheval, N. – Dougados, M., et al.: Optimal methotrexate dose is associated with better clinical outcomes than non-optimal dose in daily practice: results from the ESPOIR early arthritis cohort. *Ann Rheum Dis*, 2017, 76, s. 2054–2060.
- 10 **Rezaei, H.** – Saevarsdottir, S. – Forslind, K., et al.: In early rheumatoid arthritis, patients with a good initial response to methotrexate have excellent 2-year clinical outcomes, but radiological progression is not fully prevented: data from the methotrexate responders population in the SWEFOT trial. *Ann Rheum Dis*, 2012, 71, s. 186–191.
- 11 **Visser, K.** – van der Heijde, D.: Optimal dosage and route of administration of methotrexate in rheumatoid arthritis: a systematic review of the literature. *Ann Rheum Dis*, 2009, 68, s. 1094–1099.
- 12 **Bergstra, S. A.** – Allaart, C. F. – Stijnen, T., et al.: Meta-regression of a dose-response relationship of methotrexate in mono- and combination therapy in disease-modifying antirheumatic drug-naïve early rheumatoid arthritis patients. *Arthritis Care Res*, 2017, 69, s. 1473–1483.
- 13 **O'Dell, J. R.** – Curtis, J. R. – Mikuls, T. R., et al.: Validation of the methotrexate-first strategy in patients with early, poor-prognosis rheumatoid arthritis: results from a two-year randomized, double-blind trial. *Arthritis Rheum*, 2013, 65, s. 1985–1994.
- 14 **Moreland, L. W.** – O'Dell, J. R. – Paulus, H. E., et al.: A randomized comparative effectiveness study of oral triple therapy versus etanercept plus methotrexate in early aggressive rheumatoid arthritis: the treatment of Early Aggressive Rheumatoid Arthritis Trial. *Arthritis Rheum*, 2012, 64, s. 2824–2835.
- 15 **Goekoop-Ruiterman, Y. P.** – de Vries-Bouwstra, J. K. – Allaart, C. F., et al.: Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial. *Arthritis Rheum*, 2005, 52, s. 3381–3390.
- 16 **Schapink, L.** – van den Ende, C. H. M. – Gevers, L., et al.: The effects of methotrexate and hydroxychloroquine combination therapy vs methotrexate monotherapy in early rheumatoid arthritis patients. *Rheumatology*, 2019, 58, s. 131–134.
- 17 **Peper, S. M.** – Lew, R. – Mikuls, T., et al.: Rheumatoid arthritis treatment after methotrexate: the durability of triple therapy versus etanercept. *Arthritis Care Res*, 2017, 69, s. 1467–1472.
- 18 **Fleischmann, R.** – Tongbram, V. – van Vollenhoven, R., et al.: Systematic review and network meta-analysis of the efficacy and safety of tumour necrosis factor inhibitor-methotrexate combination therapy versus triple therapy in rheumatoid arthritis. *RMD Open*, 2017, 3, s. e000371.
- 19 **Hazlewood, G. S.** – Barnabe, C. – Tomlinson, G., et al.: Methotrexate monotherapy and methotrexate combination therapy with traditional and biologic disease modifying anti-rheumatic drugs for rheumatoid arthritis: A network meta-analysis. *Cochrane Database Syst Rev*, 2016, s. CD010227.
- 20 **Burmester, G. R.** – Kivitz, A. J. – Kupper, H., et al.: Efficacy and safety of ascending methotrexate dose in combination with adalimumab: the randomised CONCERTO trial. *Ann Rheum Dis*, 2015, 74, s. 1037–1044.
- 21 **Kaeley, G. S.** – MacCarter, D. K. – Goyal, J. R., et al.: Similar improvements in patient-reported outcomes among rheumatoid arthritis patients treated with two different doses of methotrexate in combination with adalimumab: results from the MUSICA trial. *Rheumatol Ther*, 2018, 5, s. 123–134.
- 22 **Kriekkaert, C. L.** – Nurmohamed, M. T. – Wolbink, G. J.: Methotrexate reduces immunogenicity in adalimumab treated rheumatoid arthritis patients in a dose dependent manner. *Ann Rheum Dis*, 2012, 71, s. 1914–1915.
- 23 **Hoekstra, M.** – Haagsma, C. – Neef, C., et al.: Bioavailability of higher dose methotrexate comparing oral and subcutaneous administration in patients with rheumatoid arthritis. *J Rheumatol*, 2004, 31, s. 645–648.
- 24 **Pichlmeier, U.** – Heuer, K. U.: Subcutaneous administration of methotrexate with a prefilled autoinjector pen results in a higher relative bioavailability compared with oral administration of methotrexate. *Clin Exp Rheumatol*, 2014, 32, s. 563–571.
- 25 **Mainman, H.** – McClaren, E. – Heycock, C., et al.: When should we use parenteral methotrexate? *Clin Rheumatol*, 2010, 29, s. 1093–1098.
- 26 **Hameed, B.** – Jones, H.: Subcutaneous methotrexate is well tolerated and superior to oral methotrexate in the treatment of rheumatoid arthritis. *Int J Rheum Dis*, 2010, 13, s. e83–e84.
- 27 **Bingham, S. J.** – Buch, M. H. – Lindsay, S., et al.: Parenteral methotrexate should be given before biological therapy. *Rheumatology*, 2003, 42, s. 1009–1010.
- 28 **Rozin, A.** – Schapira, D. – Balbir-Gurman, A., et al.: Relapse of rheumatoid arthritis after substitution of oral for parenteral administration of methotrexate. *Ann Rheum Dis*, 2002, 61, s. 756–757.
- 29 **Braun, J.** – Kastner, P. – Flaxenberg, P., et al.: Comparison of the clinical efficacy and safety of subcutaneous versus oral administration of methotrexate in patients with active rheumatoid arthritis: results of a six-month, multicenter, randomized, double-blind, controlled, phase IV trial. *Arthritis Rheum*, 2008, 58, s. 73–81.
- 30 **Harris, E.** – Ng, B.: Using subcutaneous methotrexate to prolong duration of methotrexate therapy in rheumatoid arthritis. *Eur J Rheumatol*, 2018, 5, s. 85–91.
- 31 **Ng, B.** – Chu, A.: Factors associated with methotrexate dosing and therapeutic decisions in veterans with rheumatoid arthritis. *Clin Rheumatol*, 2014, 33, s. 21–30.

## Biosimilární etanercept: GP2015 (Erelzi)

MUDr. David Suchý, Ph.D. Oddělení klinické farmakologie FN Plzeň

- 1 **Pavelka, K.** – Jarošová, K. – Suchý, D., et al.: První zkušenosti s biosimilárním infliximabem CT-P13 u nemocných se zánětlivými revmatickými onemocněními v České republice v národním registru ATTRA. *Čes Revmatol*, 2016, 24, s. 15–30.
- 2 **Cířská, H.** – Urbanová, M.: Biosimilars v terapii zánětlivých revmatických onemocnění. *Klin Farmakol Farm*, 2015, 29, s. 124–128.
- 3 **Yoo, D. H.** – Hrycaj, P. – Miranda, P., et al.: A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study. *Ann Rheum Dis*, 2013, 72, s. 1613–1620.
- 4 **Park, W.** – Hrycaj, P. – Jeka, S., et al.: A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study. *Ann Rheum Dis*, 2013, 72, s. 1605–1612.
- 5 **Emery, P.** – Vencovský, P. – Sylwestrak, A., et al.: A phase III randomised, double-blind, parallel-group study comparing SB4 with etanercept reference product in patients with active rheumatoid arthritis despite methotrexate therapy. *Ann Rheum Dis*, 2017, 76, s. 51–57.
- 6 **Deeks, E. D.**: GP2015: An etanercept biosimilar. *Bio Drugs*, 2017, 31, s. 555–558.
- 7 **Griffiths, C. E. M.** – Thaci, D. – Gerdes, S., et al.: The EGALITY study: a confirmatory, randomised, double-blind study comparing the efficacy, safety and immunogenicity of GP2015, a proposed etanercept biosimilar, vs. the originator product in patients with moderate-to-severe chronic plaque-type psoriasis. *Br J Dermatol*, 2017, 176, s. 928–938.
- 8 **Gerdes, S.** – Thaci, D. – Griffiths, C. E. M., et al.: Multiple switches between GP2015, an etanercept biosimilar, with originator product do not impact efficacy, safety and immunogenicity in patients with chronic plaque-type psoriasis: 30-week results from the phase 3, confirmatory EGALITY study. *J Eur Acad Dermatol Venereol*, 2018, 32, s. 420–427.
- 9 **Matucci-Cerinic, M.** – Allnore, Y. – Kavanaugh, A., et al.: Efficacy, safety and immunogenicity of GP2015, an etanercept biosimilar, compared with the reference etanercept in patients with moderate-to-severe rheumatoid arthritis: 24-week results from the comparative phase III, randomised, double-blind EQUIRA study. *RMD Open*, 2018, 4, s. e000757.
- 10 **Tischer, B.** – Mehl, A.: Patients and nurses preferences of autoinjectors for rheumatoid arthritis. *Dovepress*, 2018, 12, s. 1413–1442.

# Léčba bolesti u revmatických onemocnění

MUDr. Marta Olejárová, CSc. Revmatologický ústav a Revmatologická klinika 1. LF UK, Praha

- 1 **Olejárová, M.**: Bolesti periferních kloubů. In: Hakl, M., et al.: *Léčba bolesti*. Praha, Mladá fronta, 2019, s. 193–199.
- 2 **Pavelka, K.**: Doporučení České reumatologické společnosti pro terapii osteoartrózy kolenních, kyčelních a ručních kloubů. *Čes Revmatol*, 2012, 20, s. 138–157.
- 3 **Bruyère, O. – Cooper, C. – Pelletier, J. P., et al.**: An algorithm recommendation for the management of knee osteoarthritis in Europe and internationally: a report from a task force of the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO). *Semin Arthritis Rheum*, 2014, 44, s. 253–263.
- 4 **Smolen, J. S. – Landewé, R. – Bijlsma, J., et al.**: EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. *Ann Rheumatic Dis*, 2017, 76, s. 960–977.
- 5 **Šenolt, L. – Mann, H. – Závada, J. – Pavelka, K. – Vencovský, J.**: Doporučení České reumatologické společnosti pro farmakoterapii revmatoidní artritidy 2017. *Čes Revmatol*, 2017, 25, s. 8–24.
- 6 **Pavelka, K.**: Spondyloartritidy. In: Pavelka, K., et al.: *Farmakoterapie revmatických onemocnění*, Praha, Maxdorf, 2017, s. 201–214.
- 7 **Bečvář, R.**: Vaskulitidy velkých cév. In: Pavelka, K., et al.: *Farmakoterapie revmatických onemocnění*, Praha, Maxdorf, 2017, s. 181–185.
- 8 **Pavelka, K.**: Doporučení české reumatologické společnosti pro léčbu dny. *Čes Revmatol*, 2019, 27, s. 166–176.
- 9 **Olejárová, M.**: Fibromyalgie. In: Pavelka, K., et al.: *Farmakoterapie revmatických onemocnění*, Praha, Maxdorf, 2017, s. 312–316.
- 10 **Olejárová, M.**: Komplexní regionální bolestivý syndrom. In: Pavelka, K., et al.: *Farmakoterapie revmatických onemocnění*, Praha, Maxdorf, 2017, s. 317–322.

# Lokální nesteroidní antirevmatika v léčbě bolesti u osteoartrózy

MUDr. Olga Šlégllová Revmatologický ústav a Klinika revmatologie 1. LF UK, Praha

- 1 **Cisternas, M. G. – Murphy, L. – Sacks, J. J., et al.**: Alternative methods for defining osteoarthritis and the impact on estimating prevalence in a US population-based survey. *Arthritis Care Res (Hoboken)*, 2016, 68, s. 574–580.
- 2 **GBD 2015 DALYs and HALE Collaborators**: Global, regional, and national disability-adjusted life-years (DALYs) for 315 diseases and injuries and healthy life expectancy (HALE), 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. *Lancet*, 2016, 388, s. 1603–1658.
- 3 **Sharon, L. – Tuhina, N. – Hochberg, M. C., et al.**: 2019 American College of Rheumatology/Arthritis Foundation Guideline for management of osteoarthritis of the hand, hip and knee. *Arthr Rheumatol*, 2020, 2, s. 220–233.
- 4 **Hochberg, M. C. – Altman, R. D. – April, K. T., et al.**: American College of Rheumatology 2012 recommendations for the use of nonpharmacologic and pharmacologic therapies in osteoarthritis of the hand, hip, and knee. *Arthritis Care Res*, 2012, 64, s. 465–474.
- 5 **Bruyère, O. – Honvo, G. – Veronese, N., et al.**: An updated algorithm recommendation for the management of knee osteoarthritis from the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO). *Semin Arthritis Rheum*, 2019, 49, s. 337–350.
- 6 **Bruyère, O. – Cooper, C. – Pelletier, J. P., et al.**: An algorithm recommendation for the management of knee osteoarthritis in Europe Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO). *Semin Arthritis Rheum*, 2014, 44, s. 253–263.
- 7 **McAlindon, T. E. – Bannuru, R. R. – Sullivan, M. C., et al.**: OARSI guidelines for the non-surgical management of knee osteoarthritis. *Osteoarthritis Cartilage*, 2014, 22, s. 363–388.
- 8 **Bannuru, R. R. – Osani, M. C. – Vaysbrot, E. E., et al.**: OARSI guidelines for the non-surgical management of knee, hip, and polyarticular osteoarthritis. *Osteoarthritis and Cartilage*, 2019, 27, s. 1578–1589.
- 9 **Kloppenborg, M. – Kroon, F. P. B. – Blanco, F. J., et al.**: 2018 update of the EULAR recommendations for the management of hand osteoarthritis. *Ann Rheum Dis*, 2019, 78, s. 16–24.
- 10 **Jordan, K. M. – Arden, N. K. – Doherty, M., et al.**: EULAR Recommendations 2003: an evidence based approach to the management of knee osteoarthritis: Report of a Task Force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCI-SIT). *Ann Rheum Dis*, 2003, 62, s. 1145–1155.
- 11 **National clinical guideline centre**: *Osteoarthritis care and management in adults: methods, evidence and recommendations*. Report No. CG177. Londýn, UK: National Institute for Health and Care Excellence, 2014.
- 12 **Rannou, F. – Pelletier, J. P. – Martel-Pelletier, J.**: Efficacy and safety of topical NSAIDs in the management of osteoarthritis: evidence from real-life setting trials and surveys. *Semin Arthritis Rheum*, 2016, 45, s. 18–21.
- 13 **Raza, K. – Kumar, M. – Kumar, P., et al.**: Topical delivery of aceclofenac: challenges and promises of novel drug delivery systems. *Biomed Res Int*, 2014, s. 406731.
- 14 **McPherson, M. L. – Cimino, N. M.**: Topical NSAID formulations. *Pain Med*, 2013, 14, s. 35–39.
- 15 **Cordero, J. A. – Alarcón, L. – Escibano, L., et al.**: Study of the absorption of ketoprofen topically administered in man: comparison between tissue and plasma level. *Int J Clin Pharmacol Res*, 1986, 6, s. 69–72.
- 16 **Derry, S. – Moore, R. A. – Rabbie, R.**: Topical NSAIDs for chronic musculoskeletal pain in adults. *Cochrane Database Syst Rev*, 2012, 9, s. CD007400.
- 17 **Cordero, J. A. – Camacho, M. – Obach, R., et al.**: In vitro based index of topical anti-inflammatory activity to compare a series of NSAIDs. *Eur J Pharm Biopharm*, 2001, 51, s. 135–142.
- 18 **Haroutiunian, S. – Drennan, D. A. – Lipman, A. G.**: Topical NSAID therapy for musculoskeletal pain. *Pain Medicine*, 2010, 11, s. 535–549.
- 19 **Moore, R. A. – Derry, S. – McQuay, H. J.**: Topical agents in the treatment of rheumatic pain. *Rheumatic Disease Clinics of North America*, 2008, 34, s. 415–432.
- 20 **Evans, J. M. – McMahon, A. D. – McGilchrist, M. M., et al.**: Topical non-steroidal anti-inflammatory drugs and admission to hospital for upper gastrointestinal bleeding and perforation: a record link age case-control study. *BMJ*, 1995, 311, s. 22–26.
- 21 **Chou, R. – McDonagh, M. S. – Nakamoto, E., et al.**: Analgesics for osteoarthritis: an update of the 2006 comparative effectiveness review. Rockville, MD. Dostupné z: <http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0016485/pdf/TOC.pdf>, vyhledáno 23. 7. 2020.
- 22 **Lin, J. – Zhang, W. – Jones, A. – Doherty, M.**: Efficacy of topical non-steroidal anti-inflammatory drugs in the treatment of osteoarthritis: meta-analysis of randomised controlled trials. *Br Med J*, 2004, 13, s. 329–324.
- 23 **Moore, R. A. – Tramer, M. R. – Carroll, D., et al.**: Quantitative systematic review of topically applied non-steroidal anti-inflammatory drugs. *BMJ*, 1998, 316, s. 333–338.
- 24 **Derry, S. – Moore, R. A. – Rabbie, R.**: Topical NSAIDs for chronic musculoskeletal pain in adults. *Cochrane Database Syst Rev*, 2016, s. CD007400.
- 25 **Derry, S. – Moore, R. A. – Gaskell, H., et al.**: Topical NSAIDs for acute musculoskeletal pain in adults. *Cochrane Database Syst Rev*, 2015, s. CD007402.
- 26 **Underwood, M. – Ashby, D. – Cross, P., et al.**: Advice to use topical or oral ibuprofen for chronic knee pain in older people: randomised controlled trial and patient preference study. *Br Med J*, 2008, 336, s. 138–142.
- 27 **Blumberger, W.**: Einsparung oraler Antirheumatika durch lokale Anwendung von Etofenamat Gel. *Therapiewoche*, 1980, 30, s. 4949–4954.
- 28 **Pavelka, K.**: Doporučení České reumatologické společnosti pro léčbu osteoartrózy kolenních, kyčelních a ručních kloubů. *Čes Revmatol*, 2012, 3, s. 138–156.

# Dexketoprofen v léčbě bolesti

MUDr. Marek Hakl, Ph.D. Centrum léčby bolesti, Medicinicare, s. r. o., Chirurgická klinika FN a LF MU, Brno

- 1 **Hayball, P. J. – Nation, R. L. – Bochner, F.**: Enantioselective pharmacodynamics of the nonsteroidal antiinflammatory drug ketoprofen: in vitro inhibition of human platelet cyclooxygenase activity. *Chirality*, 1992, 4, s. 484–487.
- 2 **Mauleon, D. – Artigas, R. – Garcia, M. L. – Carganico, G.**: Preclinical and clinical development of dexketoprofen. *Drugs*, 1996, 52, suppl. 5, s. 24–45.
- 3 **Rudy, A. C. – Liu, Y. – Brater, C. – Hall, S. D.**: Stereoselective pharmacokinetics and inversion of (R)-ketoprofen in healthy volunteers. *J Clin Pharmacol*, 1998, 38, s. 35–105.
- 4 **Mazario, J. – Roza, C. – Herrero, J. F.**: The NSAID dexketoprofen trometamol is as potent as mu-opioids in the depression of wind-up and spinal cord nociceptive reflexes in normal rats. *Brain Res*, 1999, 816, s. 512–517.
- 5 **Carabaza, A. – Cabre, F. – Garcia, A. M., et al.**: Stereoselective inhibition of rat brain cyclooxygenase by dexketoprofen. *Chirality*, 1997, 9, s. 281–285.
- 6 **Moreno, J. J. – Calvo, L. – Fernandez, F., et al.**: Biological activity of ketoprofen and its optical isomers. *Eur J Pharmacol*, 1990, 183, s. 2263–2264.
- 7 **Ferrer, X. – Fernández, M. F. – Clavo, L., et al.**: Anti-inflammatory activity of S(+)-ketoprofen in the carageenan-induced paw edema of the rat. *Methods Find Exp Clin Pharmacol*, 1994, 16, suppl. 1, s. 82.
- 8 **Barbanjo, M. J. – Antonijoan, R. M. – Gich, I.**: Clinical pharmacokinetics of dexketoprofen. *Clin Pharmacokinetics*, 2001, 40, s. 245–262.
- 9 **Jamali, F. – Brocks, D. R.**: Clinical pharmacokinetics of ketoprofen and its enantiomers. *Clin Pharmacokinetics*, 1990, 19, s. 197–217.
- 10 **Gich, I. – Bayes, M. – Barbanjo, M. J., et al.**: Bioinversion of R(-)-ketoprofen following oral administration in healthy volunteers. *Clin Drug Invest*, 1996, 11, s. 347–353.
- 11 **McGurk, M. – Robinson, P. – Rajayogeswaran, V., et al.**: Clinical comparison of dexketoprofen trometamol, ketoprofen, and placebo in postoperative dental pain. *J Clin Pharmacol*, 1998, 38, s. 465–545.
- 12 **Bagan, J. V. – Lopez Arranz, J. S. – Valencia, E., et al.**: Clinical comparison of dexketoprofen trometamol and dipyrone in postoperative dental pain. *J Clin Pharmacol*, 1998, 38, s. 555–645.
- 13 **Ezcurdia, M. – Cortezoso, F. J. – Lanzon, R., et al.**: Comparison of the efficacy and tolerability of dexketoprofen and ketoprofen in the treatment of primary dysmenorrhea. *J Clin Pharmacol*, 1998, 38, s. 655–735.
- 14 **Beltran, J. – Martin-Mola, E. – Figueroa, M., et al.**: Comparison of dexketoprofen trometamol and ketoprofen in the treatment of osteoarthritis of the knee. *J Clin Pharmacol*, 1998, 38, s. 745–805.
- 15 **Doležal, T.**: Dexketoprofen. *Remedia*, 2002, 12, s. 357–359.

# Secukinumab v léčbě non-radiografické axiální spondyloartritidy

prof. MUDr. Karel Pavelka, DrSc. Revmatologický ústav, Praha

- 1 **Von Bechterew, W.**: Steifigkeit der wirbelsäule und ihre verkrümmung als besondere erkrankungsform. *Neurologischer Zentralblatt*, 1893, 12, s. 426.
- 2 **Van der Linden, S. M. – Valkenburg, H. A. – Cats, A.**: Evaluation of diagnostic criteria for ankylosing spondylitis: a proposal for modification of the New York criteria. *Arthritis Rheum*, 1984, 27, s. 361–368.
- 3 **Rudwaleit, M. – Landewé, R. – van der Heijde, D., et al.**: The development of Assessment of Spondyloarthritis International Society classification criteria for axial spondyloarthritis (part I): classification of paper patients by expert opinion including uncertainty appraisal. *Ann Rheum Dis*, 2009, 68, s. 770–776.
- 4 **Kiltz, U. – Baraliakos, X. – Karakostas, P., et al.**: Do patients with non-radiographic axial spondyloarthritis differ from patients with ankylosing spondylitis? *Arthritis Care Res*, 2012, 64, s. 1415–1422.
- 5 **Poddubnyy, D. – Sieper, J.**: Similarities and differences between

non-radiographic an radiographic axial spondyloarthritis: a clinical, epidemiological and therapeutic assessment. *Curr Opin Rheumatol*, 2014, 26, s. 377–383.

6 Medina, C. L. – Ramiro, S. – van der Heijde, D., et al.: Characteristics and burden of disease in patients with radiographic axial Spondyloarthritis: a comparison by systematic literature review and meta-analysis. *RMD Open*, 2019, 5, s. e001108, doi 10.1136/rmdopen-2019-001108.

7 Strand, V., et al.: Prevalence of axial spondyloarthritis in United States rheumatology practices. Assessment of ASAS criteria versus rheumatology expert clinical diagnosis. *Arthritis Care Res*, 2013, 65, s. 1299–1306.

8 Ghosh, N. – Ruderman, M.: No radiographic axial spondyloarthritis: clinical and therapeutic relevance. *Arthritis Res Therapy*, 2017, 19, s. 286, DOI 10.1186/s13075-017-1493-8.

9 Poddubnyy, D., et al.: Rates and predictors of radiographic progression over 2 years in patients with axial spondyloarthritis. *Ann Rheum Dis*, 2011, 70, s. 1369–1374.

10 Van der Heijde, D. – Ramiro, S. – Landewé, R., et al.: 2016 update of

the ASAS – EULAR management recommendations for axial spondyloarthritis. *Ann Rheum Dis*, 2017, 76, s. 978–991.

11 Sepriano, A. – Regel, A. – van der Heijde, D., et al.: Efficacy and safety of biological and targeted synthetic DMARD a systematic literature review informing the 2016 update of the ASAS/EULAR recommendations for the management of axial spondyloarthritis. *RMD Open*, 3, s. e000396.

12 Braun, J. – Baraliakos, X. – Doedhar, A., et al.: Effect of secukinumab on clinical and radiographic outcomes in ankylosing spondylitis: a 2-yaer results from the randomised phase III. MEASURE 1 study. *Ann Rheum Dis*, 2016, pii:annrheumdis-2016-209730, doi:10.1136/annrheumdis-2016-209730.

13 Sieper, J. – Deodhar, A. – Marzo-Ortega, H.: Secukinumab efficacy in anti-TNF naive and anti-TNF experienced subjects with active ankylosing spondylitis: results from the MEASURE 2 study. *Ann Rheum Dis*, 2016, doi:10.1136/annrheumdis-2016-210023.

14 Pavelka, K. – Kivitz, A. – Dokoupilová, E., et al.: Efficacy, safety and tolerability of secukinumab in patients with active ankylosing spondylitis: a randomized, double blind phase 3 study. MEASURE 3. *Arthritis*

*Res Ther*, 2017, 19, doi: 10.1186/s13075-017-1490-Y.

15 Deodhar, A. – Blanco, R. – Dokoupilová, E., et al.: Secukinumab 150 mg significantly improved signs and symptoms of non-radiographic axial spondyloarthritis. Results from a phase 3, double blind, randomized, placebo-controlled study. *Arthritis Rheumatol*, 2019, 71, suppl. 10, abstrakt ACR.

16 Malaviya, A. N. – Kalyani, A. – Rawat, R., et al.: Comparison of patients with ankylosing spondylitis (AS) and non-radiographic axial spondyloarthritis (nr-axSpA) from a single rheumatology clinic in New Delhi. *Int J Rheum Dis*, 2015, 18, s. 736–741.

17 Landewé, R. – Rudwaleit, M. – van der Heijde, D. M., et al.: Effect of certolizumab pegol over 48 weeks in patients with axial spondyloarthritis, including ankylosing spondylitis and non-radiographic axial spondyloarthritis. *Arthritis Rheum*, 2013, 65, suppl. 10, s. S767, abstrakt 1799.

18 Baraliakos, X. – Borah, B. – Braun, J., et al.: Long-term effects of secukinumab on MRI findings in relation to clinical efficacy in subjects with active ankylosing spondylitis: an observational study. *Ann Rheum Dis*, 2016, 75, s. 408–412, doi:10.1136/annrheumdis-2015-207544.

## Cesta k nové léčebné možnosti v terapii autoimunit: anti-IL-17A ixekizumab

MUDr. Markéta Hušáková, Ph.D. Revmatologický ústav, Praha

1 Rouvier, E., et al.: CTLA-8, cloned from an activated T cell, bearing AU-rich messenger RNA instability sequences, and homologous to a herpesvirus saimiri gene. *J Immunol*, 1993, 150, s. 5445–5456.

2 Yao, Z., et al.: Human IL-17: a novel cytokine derived from T cells. *J Immunol*, 1995, 155, s. 5483–5486.

3 Toy, D., et al.: Cutting edge: interleukin 17 signals through a heteromeric receptor complex. *J Immunol*, 2006, 177, s. 36–39.

4 Harrington, L. E., et al.: Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. *Nat Immunol*, 2005, 6, s. 1123–1132.

5 Park, H., et al.: A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17. *J Immunol*, 2006, 177, s. 36–39.

6 Liu, L., et al.: Generation and characterization of ixekizumab, a humanized monoclonal antibody that neutralizes interleukin-17A. *J Inflamm Res*, 2016, 9, s. 39–50.

7 Taltz, příbalový leták. Indianapolis, IN, Eli Lilly and Company, 2020.

8 Gordon, K. B., et al.: Phase 3 trial of ixekizumab in moderate to severe plaque psoriasis. *N Engl J Med*, 2016, 375, s. 345–356.

9 Griffiths, C. E. M., et al.: Comparison of ixekizumab with etanercept or placebo in moderate to severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials. *Lancet*, 2015, 386,

s. 541–551.

10 Leonardi, C., et al.: Efficacy and safety of ixekizumab through 5 years in moderate to severe psoriasis: long term results from UNCOVER-1 and UNCOVER-2 phase 3 randomized controlled trials. *Dermatol Ther*, 2020, 10, s. 431–447.

11 Mease, P. J., et al.: Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naïve patients with active psoriatic arthritis: results from the 24-week randomised, double-blind, placebo-controlled and active (adalimumab)-controlled period of the phase III trial SPIRIT-P1. *Ann Rheum Dis*, 2017, 76, s. 79–87.

12 Nash, P., et al.: Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: results from the 24-week randomised, double-blind, placebo-controlled period of the SPIRIT-P2 phase 3 trial. *Lancet*, 2017, 389, s. 2317–2327.

13 Chandran, V., et al.: Ixekizumab treatment of biologic-naïve patients with active psoriatic arthritis: 3-years results from phase III clinical trial (SPIRIT-P1). *Rheumatology*, 2020, kez684, doi: 10.1093/rheumatology/kez684.

14 Genovese, M. C., et al.: Safety and efficacy of ixekizumab in patients with PsA and previous inadequate response to TNF inhibitors: week

52 results from SPIRIT-P2. *Rheumatology*, 2018, 57, s. 2001–2011.

15 Sieper, J., et al.: The assessment of spondyloarthritis international society (ASAS) handbook: a guide to assess spondyloarthritis. *Ann Rheum Dis*, 2009, 68, suppl. 2, s. ii1–ii44.

16 van der Linden, S., et al.: Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. *Arthritis Rheum*, 1984, 27, s. 361–368.

17 van der Heijde, D., et al.: Ixekizumab, an interleukin-17A antagonist in the treatment of ankylosing spondylitis or radiographic axial spondyloarthritis in patients previously untreated with biological disease modifying anti-rheumatic drugs (CAOST-V): 16 week results of a phase 3 randomised, double blind, active controlles and placebo-controlled trial. *Lancet*, 2018, 392, s. 2441–2451.

18 Deodhar, A., et al.: Efficacy and safety of ixekizumab in the treatment of radiographic axial spondyloarthritis: sixteen-week results from a phase III randomized, double blind, placebo-controlled trial in patients with prior inadequate response to or intolerance of tumor necrosis factor inhibitors. *Arthritis Rheumatol*, 2019, 71, s. 599–611.

19 Deodhar, A., et al.: Ixekizumab for patients with non-radiographic axial spondyloarthritis (COAST-X): a randomised, placebo-controlled trial. *Lancet*, 2020, 395, s. 53–64.

## Febuxostat 80 mg – lékový profil

doc. MUDr. Petr Němec, Ph.D. Revmatologická ambulance II. interní kliniky, FN u sv. Anny v Brně a LF MU, Brno

1 Annemans, L. – Spaepen, E. – Gaskin, M., et al.: Gout in the UK and Germany: prevalence, comorbidities and management in general practice 2000–2005. *Ann Rheum Dis*, 2008, 67, s. 960–966.

2 European Medicines Agency. Adenuric (febuxo-stat): summary of product characteristics [online]. Dostupné z: <https://www.ema.europa.eu/en/medicines/human/EPAR/adenuric>, vyhledáno 28. 7. 2020.

3 Bruce, S. P.: Febuxostat: a selective xanthine oxidase inhibitor for the treatment of hyperuricemia and gout. *Ann Pharmacol Ther*, 2006, 40, s. 1848–1854.

4 Okamoto, K. – Eger, B. T. – Nishino, T., et al.: An extremely potent inhibitor of xanthine oxidoreductase. Crystal structure of the enzyme-inhibitor complex and mechanism of inhibition. *J Biol Chem*, 2003, 278, s. 1848–1854.

5 Okamoto, K. – Nishino, T.: Crystal structures of mammalian xanthine oxidoreductase bound with various inhibitors: allopurinol, febuxostat, and FYX-051. *J Nippon Med Sch*, 2008, 75, s. 2–3.

6 Khosravan, R. – Kukulka, M. J. – Wu, J. T., et al.: The effect of age and gender on pharmacokinetics, pharmacodynamics, and safety of febuxostat, a novel non purine selective inhibitor of xanthine oxidase. *J Clin Pharmacol*, 2008, 48, s. 1014–1024.

7 Schumacher, H. R. Jr. – Becker, M. A. – Wortmann, R. L., et al.: Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial. *Arthritis Rheum*, 2008, 59, s. 1540–1548.

8 Becker, M. A. – Schumacher, H. R., Jr. – Wortmann, R. L., et al.: Febuxostat compared with allopurinol in patients with hyperuricemia and gout. *N Engl J Med*, 2005, 353, s. 2450–2461.

9 FDA Advisory Committee Meeting 2008 for Febuxostat. Briefing Document for Advisory Committee. Takeda Pharmaceuticals North America, Inc, NDA, s. 21–856.

10 Becker, M. A. – Schumacher, H. R. – MacDonald, P. A., et al.: Clinical efficacy and safety of successful longterm urate lowering with febuxostat or allopurinol in subjects with gout. *J Rheumatol*, 2009, 36, s. 1273–1282.

11 Schumacher, H. R. Jr. – Becker, M. A. – Lloyd, E., et al.: Febuxostat in the treatment of gout: 5-year findings of the FOCUS efficacy and safety study. *Rheumatology*, 2009, 48, s. 188–194.

12 Becker, M. A. – Schumacher, H. R. Jr. – Wortmann, R. L., et al.: Febuxostat, a novel non purine selective inhibitor of xanthine oxidase:

a twenty-eight-day, multicenter, phase II, randomized, double-blind, placebo-controlled, dose-response clinical trial examining safety and efficacy in patients with gout. *Arthritis Rheum*, 2005, 52, s. 916–923.

13 White, W. B. – Saag, K. G. – Becker, M. A., et al.: Cardiovascular safety of febuxostat or allopurinol in patients with gout. *N Engl J Med*, 2018, 378, s. 1200–1210.

14 Richette, P. – Doherty, M. – Pascual, E., et al.: 2016 updated EULAR evidence-based recommendations for the management of gout. *Ann Rheum Dis*, 2017, 76, s. 29–42.

15 Mukoyoshi, M. – Nishimura, S. – Hoshida, S., et al.: In vitro drug-drug interaction studies with febuxostat, a novel non-purine selective inhibitor of xanthine oxidase: plasma protein binding, identification of metabolic enzymes and cytochrome P450 inhibition. *Xenobiotica*, 2008, 38, s. 496–510.

16 Khosravan, R. – Wu, J. T. – Joseph-Ridge, N., et al.: Pharmacokinetic interactions of concomitant administration of febuxostat and NSAIDs. *J Clin Pharmacol*, 2006, 46, s. 855–866.

## Mukopolysacharidóza I

doc. RNDr. MUDr. Pavel Ješina, Ph.D. Metabolické centrum, Klinika pediatrie a dědičných poruch metabolismu 1. LF UK a VFN, Praha

1 Poupětová, H. – Ledvinová J. – Berná, L., et al.: The birth prevalence of lysosomal storage disorders in the Czech Republic: comparison with data in different populations. *J Inher Metab Dis*, 2010, 33, s. 387–396.

2 Ješina, P. – Magner, M. – Poupětová, H., et al.: Mukopolysacharidóza I – klinické projevy u 24 dětí z České republiky a Slovenska. *Čes-slov Pediatr*, 2011, 66, s. 6–11.

3 Michalík, J. – Valenta, M. – Honzík, T., et al.: Kvalita života osob pečujících o dítě s dědičným metabolickým onemocněním. *Čes-slov Pediatr*, 2012, 67, s. 376–384.

4 Malinová, V. – Honzík, T.: Lysosomální onemocnění – současné možnosti diagnostiky a terapie. *Pediatr pro Praxi*, 2013, 14, s. 157–160.

5 Clarke, L. A. – Hollak, C. E.: The clinical spectrum and pathophysiology of skeletal complications in lysosomal storage disorders. *Best Pract*

*Res Clin Endocrinol Metab*, 2015, 29, s. 219–235.

6 Ješina, P.: Revmatologické projevy u pacientů s mukopolysacharidózou. *Acta Medicinæ*, 2015, 6, s. 62–66.

7 Wraith, J. E. – Jones, S.: Mukopolysacharidóza type I. *Pediatr Endocrinol Rev*, 2014, 12, suppl. 1, s. 102–106.

8 Morishita, K. – Petty, R. E., et al.: Musculoskeletal manifestations of mukopolysacharidóza. *Rheumatology*, 2011, 50, s. 19–25.

# Kardiovaskulární riziko při léčbě inhibitory Janus kináz v revmatologii

MUDr. Sabina Oreská Revmatologický ústav a Revmatologická klinika, 1. LF UK, Praha

- Mackey, R. H. – Kuller, L. H. – Moreland, L. W.: Update on cardiovascular disease risk in patients with rheumatic diseases. *Rheum Dis Clin North Am*, 2018, 44, s. 475–487.
- Sanjodi, M., et al.: Atherosclerosis and autoimmunity: a growing relationship. *Int J Rheum Dis*, 2018, 21, s. 908–921.
- Atzeni, F. – Svenungsson, E. – Nurmohamed, M. T.: Do DMARDs and biologic agents protect from cardiovascular disease in patients with inflammatory arthropathies? *Autoimmun Rev*, 2019, 18, s. 102401.
- Castaneda, S., et al.: Cardiovascular morbidity and associated risk factors in Spanish patients with chronic inflammatory rheumatic diseases attending rheumatology clinics: Baseline data of the CARMA Project. *Semin Arthritis Rheum*, 2015, 44, s. 618–626.
- Avina-Zubieta, J. A., et al.: Risk of cardiovascular mortality in patients with rheumatoid arthritis: a meta-analysis of observational studies. *Arthritis Rheum*, 2008, 59, s. 1690–1697.
- Holmqvist, M. E., et al.: Risk of venous thromboembolism in patients with rheumatoid arthritis and association with disease duration and hospitalization. *JAMA*, 2012, 308, s. 1350–1356.
- Rathore, M. S. – Shekhawat, N. S.: In vitro regeneration in *Sarcostema acidum* (Roxb.) – an important medicinal plant of semi-arid ecosystem of Rajasthan, India. *Physiol Mol Biol Plants*, 2013, 19, s. 269–275.
- Agca, R., et al.: EULAR recommendations for cardiovascular disease risk management in patients with rheumatoid arthritis and other forms of inflammatory joint disorders: 2015/2016 update. *Ann Rheum Dis*, 2017, 76, s. 17–28.
- Reiner, R. – Catapano, A. L. – De Backer, G., et al.: ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). *Eur Heart J*, 2011, 32, s. 1769–1818.
- Anderson, K. M., et al.: Cardiovascular disease risk profiles. *Am Heart J*, 1991, 121, s. 293–298.
- Kerekes, G., et al.: Validated methods for assessment of subclinical atherosclerosis in rheumatology. *Nat Rev Rheumatol*, 2012, 8, s. 224–234.
- Ramonda, R., et al.: Atherosclerosis in psoriatic arthritis. *Autoimmun Rev*, 2011, 10, s. 773–778.
- Kang, E. H. – Liao, K. P. – Kim, S. C.: Cardiovascular safety of biologics and JAK inhibitors in patients with rheumatoid arthritis. *Curr Rheumatol Rep*, 2018, 20, s. 42.
- Sepriano, A., et al.: Safety of synthetic and biological DMARDs: a systematic literature review informing the 2019 update of the EULAR recommendations for the management of rheumatoid arthritis. *Ann Rheum Dis*, 2020, 79, s. 760–770.
- Smolen, J. S., et al.: Proposal for a new nomenclature of disease-modifying antirheumatic drugs. *Ann Rheum Dis*, 2014, 73, s. 3–5.
- Smolen, J. S., et al.: EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. *Ann Rheum Dis*, 2020, 79, s. 685–699.
- Cioffi, G., et al.: Incidence and predictors of adverse clinical events in patients with rheumatoid arthritis and asymptomatic left ventricular systolic dysfunction. *Clin Exp Rheumatol*, 2020, 38, s. 420–427.
- Charles-Schoeman, C., et al.: Association of triple therapy with improvement in cholesterol profiles over two-year followup in the treatment of early aggressive rheumatoid arthritis trial. *Arthritis Rheumatol*, 2016, 68, s. 577–586.
- Widdifield, J., et al.: Associations between methotrexate use and the risk of cardiovascular events in patients with elderly-onset rheumatoid arthritis. *J Rheumatol*, 2019, 46, s. 467–474.
- Tracey, D., et al.: Tumor necrosis factor antagonist mechanisms of action: a comprehensive review. *Pharmacol Ther*, 2008, 117, s. 244–279.
- Dixon, W. G., et al.: Reduction in the incidence of myocardial infarction in patients with rheumatoid arthritis who respond to anti-tumor necrosis factor alpha therapy: results from the British Society for Rheumatology Biologics Register. *Arthritis Rheum*, 2007, 56, s. 2905–2912.
- Conti, F., et al.: The influence of comorbidities on the efficacy of tumor necrosis factor inhibitors, and the effect of tumour necrosis factor inhibitors on comorbidities in rheumatoid arthritis: report from a National Consensus Conference. *Rheumatology (Oxford)*, 2018, 57, s. vii1–vii22.
- Daen, C. I., et al.: Effect of TNF inhibitors on lipid profile in rheumatoid arthritis: a systematic review with meta-analysis. *Ann Rheum Dis*, 2012, 71, s. 862–868.
- Nurmohamed, M., et al.: Longer durations of antitumour necrosis factor treatment are associated with reduced risk of cardiovascular events in patients with rheumatoid arthritis. *RMD Open*, 2015, 1, s. e000080.
- Souto, A., et al.: Lipid profile changes in patients with chronic inflammatory arthritis treated with biologic agents and tofacitinib in randomized clinical trials: a systematic review and meta-analysis. *Arthritis Rheumatol*, 2015, 67, s. 117–127.
- Genovese, M. C., et al.: Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study. *Arthritis Rheum*, 2008, 58, s. 2968–2980.
- Raterman, H. G., et al.: HDL protein composition alters from proatherogenic into less atherogenic and proinflammatory in rheumatoid arthritis patients responding to rituximab. *Ann Rheum Dis*, 2013, 72, s. 560–565.
- Benucci, M., et al.: Factors correlated with improvement of endothelial dysfunction during rituximab therapy in patients with rheumatoid arthritis. *Biologics*, 2013, 7, s. 69–75.
- Hunter, C., et al.: Utilizing end-tidal carbon dioxide to diagnose diabetic ketoacidosis in prehospital patients with hyperglycemia. *Prehosp Disaster Med*, 2020, 35, s. 281–284.
- Kato, M.: New insights into IFN-gamma in rheumatoid arthritis: role in the era of JAK inhibitors. *Immunol Med*, 2020, s. 1–7.
- Johnson, H. M. – Noon-Song, E. – Ahmed, C. M.: Noncanonical IFN signaling, steroids, and STATs: a probable role of V-ATPase. *Mediators Inflamm*, 2019, 2019, s. 4143604.
- Itcho, K., et al.: Angiotensin 1-7 suppresses angiotensin II mediated aldosterone production via JAK/STAT signaling inhibition. *J Steroid Biochem Mol Biol*, 2019, 185, s. 137–141.
- Lees, J. R.: Interferon gamma in autoimmunity: A complicated player on a complex stage. *Cytokine*, 2015, 74, s. 18–26.
- Van Gool, S. W., et al.: T helper-independent activation of human CD8+ cells: the role of CD28 costimulation. *Scand J Immunol*, 1996, 44, s. 21–29.
- Yang, X., et al.: Inhibition of JAK2/STAT3/SOCS3 signaling attenuates atherosclerosis in rabbit. *BMC Cardiovasc Disord*, 2020, s. 133.
- Smolen, J. S., et al.: EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. *Ann Rheum Dis*, 2017, 76, s. 960–977.
- Singh, J. A., et al.: 2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. *Arthritis Rheumatol*, 2016, 68, s. 1–26.
- Serhal, L. – Edwards, C. J.: Upadacitinib for the treatment of rheumatoid arthritis. *Expert Rev Clin Immunol*, 2019, 15, s. 13–25.
- Genovese, M. C., et al.: Safety and efficacy of upadacitinib in patients with active rheumatoid arthritis refractory to biologic disease-modifying anti-rheumatic drugs (SELECT-BEYOND): a double-blind, randomized controlled phase 3 trial. *Lancet*, 2018, 391, s. 2513–2524.
- Burmester, G. R., et al.: Safety and efficacy of upadacitinib in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying anti-rheumatic drugs (SELECT-NEXT): a randomised, double-blind, placebo-controlled phase 3 trial. *Lancet*, 2018, 391, s. 2503–2512.
- Smolen, J. S., et al.: Upadacitinib as monotherapy in patients with active rheumatoid arthritis and inadequate response to methotrexate (SELECT-MONOTHERAPY): a randomised, placebo-controlled, double-blind phase 3 study. *Lancet*, 2019, 393, s. 2303–2311.
- Kerschbaumer, A., et al.: Pharmacological treatment of psoriatic arthritis: a systematic literature research for the 2019 update of the EULAR recommendations for the management of psoriatic arthritis. *Ann Rheum Dis*, 2020, 79, s. 778–786.
- Merola, J. F., et al.: Tofacitinib in psoriatic arthritis patients: skin signs and symptoms and health-related quality of life from two randomized phase 3 studies. *J Eur Acad Dermatol Venereol*, 2020.
- Nash, P., et al.: Efficacy of tofacitinib for the treatment of psoriatic arthritis: pooled analysis of two phase 3 studies. *Rheumatol Ther*, 2018, 5, s. 567–582.
- Mease, P., et al.: Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active psoriatic arthritis (EQUATOR): results from a randomised, placebo-controlled, phase 2 trial. *Lancet*, 2018, 392, s. 2367–2377.
- Šenolt, L., et al.: Doporučení České revmatologické společnosti pro farmakoterapii revmatoidní artritidy 2017. *Čes Revmatol*, 2017, 25, s. 8–24.
- Song, C., et al.: Triptolide attenuates lipopolysaccharide-induced inflammatory responses in human endothelial cells: involvement of NF-kappaB pathway. *BMC Complement Altern Med*, 2019, 19, s. 198.
- Demyanets, S. – Huber, K. – Wojta, J.: Vascular effects of glycoprotein130 ligands-part I: pathophysiological role. *Vascul Pharmacol*, 2012, 56, s. 34–46.
- Liao, M., et al.: Local and systemic alterations in signal transducers and activators of transcription (STAT) associated with human abdominal aortic aneurysms. *J Surg Res*, 2012, 176, s. 321–328.
- Manea, A., et al.: Jak/STAT signaling pathway regulates nox1 and nox4-based NADPH oxidase in human aortic smooth muscle cells. *Arterioscler Thromb Vasc Biol*, 2010, 30, s. 105–112.
- Mo, Z. C., et al.: AOPPs inhibits cholesterol efflux by down-regulating ABCA1 expression in a JAK/STAT signaling pathway-dependent manner. *J Atheroscler Thromb*, 2011, 18, s. 796–807.
- Wang, Z., et al.: Tofacitinib ameliorates atherosclerosis and reduces foam cell formation in apoE deficient mice. *Biochem Biophys Res Commun*, 2017, 490, s. 194–201.
- Dutzmann, J., et al.: Emerging translational approaches to target STAT3 signalling and its impact on vascular disease. *Cardiovasc Res*, 2015, 106, s. 365–374.
- Youn, S. W. – Park, K. K.: Small-nucleic-acid-based therapeutic strategy targeting the transcription factors regulating the vascular inflammation, remodeling and fibrosis in atherosclerosis. *Int J Mol Sci*, 2015, 16, s. 11804–11833.
- Kume, K., et al.: Tofacitinib improves atherosclerosis despite up-regulating serum cholesterol in patients with active rheumatoid arthritis: a cohort study. *Rheumatol Int*, 2017, 37, s. 2079–2085.
- Winthrop, K. L.: The emerging safety profile of JAK inhibitors in rheumatic disease. *Nat Rev Rheumatol*, 2017, 13, s. 320.
- Charles-Schoeman, C., et al.: Cardiovascular safety findings in patients with rheumatoid arthritis treated with tofacitinib, an oral Janus kinase inhibitor. *Semin Arthritis Rheum*, 2016, 46, s. 261–271.
- Smolen, J. S., et al.: Safety profile of baricitinib in patients with active rheumatoid arthritis with over 2 years median time in treatment. *J Rheumatol*, 2019, 46, s. 7–18.
- Kremer, J. M., et al.: Effects of baricitinib on lipid, apolipoprotein, and lipoprotein particle profiles in a phase IIb study of patients with active rheumatoid arthritis. *Arthritis Rheumatol*, 2017, 69, s. 943–952.
- Taylor, P. C., et al.: Lipid profile and effect of statin treatment in pooled phase II and phase III baricitinib studies. *Ann Rheum Dis*, 2018, 77, s. 988–995.
- Verden, A., et al.: Analysis of spontaneous postmarket case reports submitted to the FDA regarding thromboembolic adverse events and JAK inhibitors. *Drug Saf*, 2018, 41, s. 357–361.
- Xie, W., et al.: Impact of Janus kinase inhibitors on risk of cardiovascular events in patients with rheumatoid arthritis: systematic review and meta-analysis of randomised controlled trials. *Ann Rheum Dis*, 2019, 78, s. 1048–1054.
- Fleischmann, R. M., et al.: Safety and effectiveness of upadacitinib or adalimumab plus methotrexate in patients with rheumatoid arthritis over 48 weeks with switch to alternate therapy in patients with insufficient response. *Ann Rheum Dis*, 2019, 78, s. 1454–1462.
- Perez-Baos, S., et al.: Tofacitinib restores the inhibition of reverse cholesterol transport induced by inflammation: understanding the lipid paradox associated with rheumatoid arthritis. *Br J Pharmacol*, 2017, 174, s. 3018–3031.
- Charles-Schoeman, C., et al.: Potential mechanisms leading to the abnormal lipid profile in patients with rheumatoid arthritis versus healthy volunteers and reversal by tofacitinib. *Arthritis Rheumatol*, 2015, 67, s. 616–625.
- Charles-Schoeman, C., et al.: Effects of tofacitinib and other DMARDs on lipid profiles in rheumatoid arthritis: implications for the rheumatologist. *Semin Arthritis Rheum*, 2016, 46, s. 71–80.
- Pfizer Inc. Tofacitinib for the treatment of rheumatoid arthritis. NDA 203214. Dostupné z: [www.accessdata.fda.gov/drugsatfda\\_docs/nda/2012/203214orig1s000med.pdf](http://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/203214orig1s000med.pdf), vyhledáno 28. 1. 2018.
- van den Oever, I. A. – Sattar, M. – Nurmohamed, M. T.: Thromboembolic and cardiovascular risk in rheumatoid arthritis: role of the haemostatic system. *Ann Rheum Dis*, 2014, 73, s. 954–957.
- Kim, S. C., et al.: Risk of venous thromboembolism in patients with rheumatoid arthritis: initiating disease-modifying antirheumatic drugs. *Am J Med*, 2015, 128, s. 539 e7–17.
- Scott, I. C. – Hider, S. L. – Scott, D. L.: Thromboembolism with Janus kinase (JAK) inhibitors for rheumatoid arthritis: How real is the risk? *Drug Saf*, 2018, 41, s. 645–653.
- Taylor, P. C., et al.: Cardiovascular safety during treatment with baricitinib in rheumatoid arthritis. *Arthritis Rheumatol*, 2019, 71, s. 1042–1055.
- Hodge, J. A.: The mechanism of action of tofacitinib – an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis. *Clin Exp Rheumatol*, 2016, 34, s. 318–328.

# Plicní arteriální hypertenze u systémových onemocnění pojiva

doc. MUDr. Radim Bečvář, CSc. Revmatologický ústav a Revmatologická klinika 1. LF UK, Praha

- Galie, N. – Manes, A., et al.: Pulmonary arterial hypertension associated to connective tissue diseases. *Lupus*, 2005, 14, s. 713–717.
- Mukerjee, D. – St George, D., et al.: Prevalence and outcome in systemic sclerosis associated pulmonary arterial hypertension: application of a registry approach. *Ann Rheum Dis*, 2003, 62, s. 1088–1093.
- Humbert, M. – Sitbon, O., et al.: Pulmonary arterial hypertension in France. Results from a national registry. *Am J Respir Crit Care Med*, 2006, 173, s. 1203–1230.
- Jansa, P. – Becvar, R., et al.: Pulmonary Arterial Hypertension Association with Systemic Sclerosis in the Czech Republic. *Clin Rheumatol*, 2012, 31, s. 557–561.
- Pan, T. L. – Thumboo, J. – Boey, M. L.: Primary and secondary pulmonary hypertension in systemic lupus erythematosus. *Lupus*, 2000, 9, s. 338–342.
- Prabu, A. – Patel, K., et al.: Prevalence and risk factors for pulmonary arterial hypertension in patients with lupus. *Rheumatology (Oxford)*, 2009, 48, s. 1506–1511.
- Dawson, J. K. – Goodson, N. G., et al.: Raised pulmonary artery pressures measured with Doppler echocardiography in rheumatoid arthritis patients. *Rheumatology (Oxford)*, 2000, 39, s. 1320–1325.
- Udayakumar, N. – Venkatesan, S., et al.: Pulmonary hypertension in rheumatoid arthritis—relation with the duration of the disease. *Int J Cardiol*, 2008, 127, s. 410–412.
- Fagan, K. A. – Badesch, D. B.: Pulmonary hypertension associated with connective tissue disease. *Prog Cardiovasc Dis*, 2002, 45, s. 225–234.
- Jeon, C. H. – Chai, J. Y. – Seo, Y. I.: Pulmonary hypertension associated with rheumatic diseases: baseline characteristics from the Korean registry. *Int J Rheum Dis*, 2013, 16, s. 789.
- Sullivan, W. D. – Hurst, D. J., et al.: A prospective evaluation emphasizing pulmonary involvement in patients with mixed connective tissue disease. *Medicine (Baltimore)*, 1984, 63, s. 92–107.
- Yang, X. – Mardekian, J., et al.: Prevalence of pulmonary arterial hypertension in patients with connective tissue diseases: a systematic review of the literature. *Clin Rheumatol*, 2013, 32, s. 1519–1531.
- Farber, H. W. – Loscalzo, J.: Pulmonary arterial hypertension – mechanism of disease. *N Engl J Med*, 2004, 351, s. 1655–1665.
- Shahane, A.: Pulmonary hypertension in rheumatic diseases: epidemiology and pathogenesis. *Rheumatol Int*, 2013, 33, s. 1655–1667.
- Jansa, P. – Aschermann, M., et al.: Plicní arteriální hypertenze u systémových onemocnění pojiva. *Rheumatologia*, 2006, 20, s. 13–18.
- Simonneau, G. – Galie, N., et al.: Clinical classification of pulmonary hypertension. *J Am Coll Cardiol*, 2004, 43, s. 55–125.
- Khanna, D. – Gladue, H. – Channick, R., et al.: Recommendations for screening and detection of connective tissue disease associated pulmonary arterial hypertension. *Arthritis Rheum*, 2013, 65, s. 3194–3201.
- Coghlan, J. G. – Denton, C. P. – Grunig, E., et al.: Evidence-based detection of pulmonary arterial hypertension in systemic sclerosis: the DETECT study. *Ann Rheum Dis*, 2014, 73, s. 1340–1349.
- Allanore, Y. – Borderie, D. – Avouac, J., et al.: High N-terminal pro-brain natriuretic peptide levels and low diffusing capacity for carbon monoxide as independent predictors of the occurrence of precapillary pulmonary arterial hypertension in patients with systemic sclerosis. *Arthritis Rheum*, 2008, 58, s. 284–291.
- Thakkar, V. – Stevens, W. M. – Prior, D., et al.: N-terminal pro-brain natriuretic peptide in a novel screening algorithm for pulmonary arterial hypertension in systemic sclerosis: a case-control study. *Arthritis Res Ther*, 2012, 14, R143.
- Montani, D. – Achouh, L. – Dorfmueller, P., et al.: Pulmonary veno-occlusive disease: clinical, functional, radiologic, and hemodynamic characteristics and outcome of 24 cases confirmed by histology. *Medicine (Baltimore)*, 2008, 87, s. 220–233.
- Jansa, P. – Bečvář, R., et al.: Výskyt a časná detekce plicní arteriální hypertenze u systémové sklerodermie v ČR. *Postgraduální medicína*, 2012, 14, příl. 1 Vybrané kapitoly z kardiologie, s. 42–48.
- McGoan, M. – Gutterman, D., et al.: Screening, early detection, and diagnosis of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. *Chest*, 2004, 126, s. 145–345.
- Galiè, N. – Corris, P. A. – Frost, A., et al.: Updated treatment algorithm of pulmonary arterial hypertension. *J Am Coll Cardiol*, 2013, 62, s. D60–D72.
- Badesch, D. B. – Tapson, V. F. – McGoan, M. D., et al.: Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial. *Ann Intern Med*, 2000, 132, s. 425–434.
- Olschewski, H. – Simonneau, G. – Galiè, N., et al.: Inhaled iloprost for severe pulmonary hypertension. *N Engl J Med*, 2002, 347, s. 322–331.
- Barst, R. J. – McGoan, M. D. – McLaughlin, V. V., et al.: Beraprost therapy for pulmonary arterial hypertension. *J Am Coll Cardiol*, 2003, 41, s. 2119–2125.
- Gainey, S. – Chin, K. – Coghlan, G., et al.: Selexipag for the treatment of connective tissue disease-associated pulmonary arterial hypertension. *Eur Respir J*, 2017, 50, s. 160249353.
- Denton, C. P. – Humbert, M. – Rubin, L. – Black, C. M.: Bosentan treatment for pulmonary arterial hypertension related to connective tissue disease: a subgroup analysis of the pivotal clinical trials and their open-label extensions. *Ann Rheum Dis*, 2006, 65, s. 1336–1340.
- Galiè, N. – Olschewski, H. – Oudiz, R. J., et al.: Ambrisentan for the treatment of pulmonary arterial hypertension: Results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2. *Circulation*, 2008, 117, s. 3010–3019.
- Pulido, T. – Adzerikho, I. – Channick, R. N., et al.: Macitentan and morbidity and mortality in pulmonary arterial hypertension. *N Engl J Med*, 2013, 369, s. 809–818.
- Sitbon, O. – Delcroix, M. – Bergot, E., et al.: EPITOME-2: An open-label study assessing the transition to a new formulation of intravenous poprostenol in patients with pulmonary arterial hypertension. *Am Heart J*, 2014, 167, s. 210–217.
- Humbert, M. – Coghlan, J. G. – Ghofrani, H. A., et al.: Riociguat for the treatment of pulmonary arterial hypertension associated with connective tissue disease: results from PATENT-1 and PATENT-2. *Ann Rheum Dis*, 2017, 76, s. 422–426.
- Kowal-Bielecka, O. – Fransen, J. – Avouac, J., et al.: The EUSTAR co-authors: Update of EULAR recommendations for the treatment of systemic sclerosis. *Ann Rheum Dis*, 2017, 76, s. 1327–1339.
- Hernández-Sánchez, J. – Harlow, L. – Church, C., et al.: Clinical trial protocol for TRANSFORM-UK: A therapeutic open-label study of tocilizumab in the treatment of pulmonary arterial hypertension. *Pulm Circ*, 2018, 8, s. 2045893217735820.
- Simonneau, G. – Hoeper, M. M. – McLaughlin, V., et al.: Future perspectives in pulmonary arterial hypertension. *Eur Respir Rev*, 2016, 25, s. 381–389.
- Jansa, P. – Aschermann, M., et al.: Plicní arteriální hypertenze u systémových onemocnění pojiva. *Rheumatologia*, 2006, 20, s. 13–18.

## Pleiotropní efekt vitaminu D

doc. MUDr. Václav Vyskočil, Ph.D. II. interní klinika – klinika ortopedie a traumatologie pohybového ústrojí LF UK a FN Plzeň

- Chapuy, M. C. – Arlot, M. E. – Duboeuf, F., et al.: Vitamin D3 and calcium to prevent hip fractures in elderly women. *New Eng J Med*, 1992, 327, s. 1637–1642.
- Meunier, P. J. – Pamphile, R. – Chapuy, M. C., et al.: A calcium-vitamin D3 combined supplementation is cost-saving for preventing hip fractures in institutionalised elderly women: an economic evaluation from the perspective of seven European countries (Belgium, France, Germany, The Netherlands, Spain, Sweden, United Kingdom). *Osteoporosis International*, 2002, 13, suppl. 1, s. S14.
- Bischoff-Ferrari, H. A. – Orav, E. J. – Dawson-Hughes, B.: Effect of cholecalciferol plus calcium on falling in ambulatory older men and women: a 3-year randomized controlled trial. *Archives of Internal Medicine*, 2006, 166, s. 424–430.
- Chapuy, M. C. – Pamphile, R. – Paris, E., et al.: Combined calcium and vitamin D3 supplementation in elderly women: confirmation of reversal of secondary hyperparathyroidism and hip fracture risk: the Decalys II study. *Osteoporosis Int*, 2002, 13, s. 257–264.
- Lappe, J. M. – Travers-Gustafson, D. – Davies, K. M., et al.: Vitamin D and calcium supplementation reduces cancer risk: results of a randomized trial. *Am J Clin Nutr*, 2007, 85, s. 1586–1591.
- Lewis, J. R. – Schousboe, J. T. – Lim, W. H., et al.: Long-term atherosclerotic vascular disease risk and prognosis in elderly women with abdominal aortic calcification on lateral spine images captured during bone density testing: a prospective study. *J Bone Miner Res*, 2018, 33, s. 1001–1010.
- Berezowska, M. – Coe, S. – Dawes, H.: Effectiveness of vitamin D supplementation in the management of multiple sclerosis: a systematic review. *Int J Mol Sci*, 2019, 20, s. 1301.
- Li, J. – Gao, Y. – Yu, T., et al.: Obesity and leptin influence vitamin D metabolism and action in human marrow stromal cells. *J Steroid Biochem Mol Biol*, 2020, 198, s. 105564.
- Christakos, S.: Mechanism of action of 1,25-dihydroxyvitamin D3 on intestinal calcium absorption. *Rev Endocr Metab Disord*, 2012, 13, s. 39–44.
- Sepulveda-Villegas, M. – Elizondo-Montemayor, L. – Trevino, V.: Identification and analysis of 35 genes associated with vitamin D deficiency: A systematic review to identify genetic variants. *J Steroid Biochem Mol Biol*, 2020, 196, s. 105516.
- Liu, Y. – Wang, M. – Xu, W., et al.: Active vitamin D supplementation alleviates initiation and progression of nonalcoholic fatty liver disease by repressing the p53 pathway. *Life Sci*, 2020, 241, s. 117086.
- Ogdu, D. – Xia, E. – Sun, J.: Gut instincts: vitamin D/vitamin D receptor and microbiome in neurodevelopment disorders. *Open Biol*, 2020, 10, s. 200063.
- Christakos, S. – Li, S. – De La Cruz, J., et al.: Vitamin D and the intestine: review and update. *J Steroid Biochem Mol Biol*, 2020, 196, s. 105501.
- Kow, C. S. – Hadi, M. A. – Hasan, S. S.: Vitamin D supplementation in influenza and COVID-19 infections comment on: evidence that vitamin D supplementation could reduce risk of influenza and COVID-19 infections and deaths. *Nutrients*, 2020, 12, s. 988.
- Reins, R. Y. – McDermott, A. M.: Vitamin D: implications for ocular disease and therapeutic potential. *Exp Eye Res*, 2015, 134, s. 101–110.
- Minisola, S. – Colangelo, L. – Pepe, J., et al.: Vitamin D screening. *J Endocrinol Invest*, 2020, 43, s. 1047–1051.
- Zhang, X. – Huang, X.-Z. – Chen, W.-J., et al.: Plasma 25-hydroxyvitamin D levels, vitamin D intake, and pancreatic cancer risk or mortality: a meta-analysis. *Oncotarget*, 2017, 8, s. 64395–64406.
- Cannon, T. L. – Ford, J. – Hester, D. – Trump, D. L.: The incidental use of high-dose vitamin D3 in pancreatic cancer. *Case Reports in Pancreatic Cancer*, 2016, 2, s. 32–35.
- Stolzenberg-Solomon, R. Z. – Vieth, R. – Azad, A., et al.: A prospective nested case-control study of vitamin D status and pancreatic cancer risk in male smokers. *Cancer Res*, 2006, 66, s. 10213–10219.